Treatment To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis: An Update
Additional Possible Adverse Effects
These potentially severe adverse effects are listed by the FDA but are not findings of the CER:
Alendronate, risedronate, and ibandronate are associated with musculoskeletal pain, hypocalcemia, osteonecrosis of the jaw, and severe irritation of the upper gastrointestinal mucosa.
Zoledronic acid is associated with musculoskeletal pain, renal toxicity and failure, and atrial fibrillation.
Denosumab is associated with hypocalcemia and osteonecrosis of the jaw.
Teriparatide is associated with an increased risk of bone cancer.
Symptoms of vitamin D toxicity include nausea, vomiting, anorexia, polyuria, constipation, weakness, and weight loss. Excessive vitamin D causes hypercalcemia, which can cause dementia, memory loss, and arrhythmias, as well as irreversible kidney damage and renal failure.
Keywords: Bone | low bone density | bone density | osteoporosis | fracture | osteopenia | skeletal | teriparatide | hypercalcemia | hypocalcemia | bisphosphonate | alendronate | risedronate | ibandronate | zoledronic acid | denosumab | vitamin D | musculoskeletal pain | osteonecrosis of the jaw | ONJ | renal toxicity | renal failure | bone cancer | vitamin D toxicity | atrial fibrillation | gastrointestinal mucosa | arrhythmia
- Newberry SJ, Crandall CC, Gellad WG, et al. Treatment To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis: An Update to the 2007 Report. Comparative Effectiveness Review No. 53 (Prepared by the Southern California Evidence-based Practice Center under Contract No. HHSA 290-2007-10062-I). Rockville, MD: Agency for Healthcare Research and Quality; February 2012. AHRQ Publication No. 12-EHC023-EF. Available at www.effectivehealthcare.ahrq.gov/reports/lbd.cfm.
Your slide tray is being processed.